Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Michael Klichinsky"'
Autor:
Shirley Chen, Shengdar Q. Tsai, Tae Hoon Shin, Michael Klichinsky, Jennifer J.D. Morrissette, Miroslaw Kozlowski, Douglas B. Kuhns, Miriam Y. Kim, Gregory K. Behbehani, Adam Bagg, Cynthia E. Dunbar, Kyung-Rok Yu, Saar Gill, Daniel M. Schreeder, Xinhe Shan, Katherine R. Calvo, Saad S. Kenderian, Maksim Shestov, Robert E. Donahue, Aisha A. AlJanahi, Cicera R. Lazzarotto, Olga Shestova, Palak Sekhri, Marco Ruella, Katherine D. Cummins
Publikováno v:
Cell. 173(6)
The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results i
Autor:
Olga Shestova, Sheila R Gill, Vania Aikawa, Michael C Carroll, Michael Klichinsky, David L. Porter, John Scholler, Marco Ruella, Carl H. June, De-Gang Song, Saad S. Kenderian, Jennifer J.D. Morrissette
Publikováno v:
Leukemia. 29(8)
Patients with chemo-refractory acute myeloid leukemia (AML) have a dismal prognosis. Chimeric antigen receptor T (CART) cell therapy has produced exciting results in CD19+ malignancies and may overcome many of the limitations of conventional leukemia
Autor:
Marco Ruella, Olga Schestova, Miroslaw Kozlowski, Daniel M. Schreeder, Saar Gill, Michael Klichinsky, Saad S. Kenderian, Miriam Y. Kim
Publikováno v:
Molecular Therapy. 24:S108
Antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells or bispecific T cell engaging (BITE) antibodies directed against CD19 leads to elimination of malignant and normal B cells. These approaches have a broad therapeutic index i
Autor:
Decheng Song, John Scholler, Michael Klichinsky, Saar Gill, David L. Porter, Olga Shestova, Saad S. Kenderian, Carl H. June, Marco Ruella, Martin Carroll
Publikováno v:
Cancer Research. 75:3139-3139
Allogeneic stem cell transplantation is the only option in relapsed acute myeloid leukemia (AML). However, patients are often excluded due to refractory disease. The successful translation of Chimeric Antigen Receptor (CAR) T cell therapy to AML woul
Autor:
Olga Shestova, Saad S. Kenderian, Michael Klichinsky, David L. Porter, Decheng Song, John Scholler, Saar Gill, Carl H. June, Martin Carroll, Marco Ruella
Publikováno v:
Biology of Blood and Marrow Transplantation. (2):S25-S26